



The Commonwealth of Massachusetts

Executive Office of Health and Human Services
Department of Public Health
Bureau of Infectious Disease and Laboratory Sciences
305 South Street, Jamaica Plain, MA 02130

MAURA T. HEALEY
Governor

KIMBERLEY DRISCOLL
Lieutenant Governor

KATHLEEN E. WALSH
Secretary

ROBERT GOLDSTEIN, MD, PhD
Commissioner

Tel: 617-624-6000

www.mass.gov/dph

To: Massachusetts Healthcare Providers
From: Massachusetts Department of Public Health
Re: Botulism cases linked to cosmetic botulinum toxin (Botox)
Date: June 5, 2025

The Massachusetts Department of Public Health (DPH) is investigating four recent cases of suspect botulism linked to cosmetic botulinum toxin (Botox) injections in the South Shore area. These cases highlight the risk of iatrogenic botulism, a rare but serious adverse event resulting from the administration of botulinum toxin products. DPH is advising healthcare providers to be alert for symptoms consistent with botulism occurring after botulinum toxin injections.

Background:

Botulinum toxin (Botox) is widely used for cosmetic purposes to reduce wrinkles and fine lines. While generally safe when administered by trained professionals, improper dosing, administration technique, or use of non-FDA-approved products may increase the risk of systemic botulism symptoms. Botulism is the rare and sometimes fatal disease caused by botulinum toxin circulating in the blood and producing effects remotely from the injection site. There may be symptom overlap between the presentation of localized adverse effects from injection of botulinum toxin, especially in the head and neck, and the early symptoms of botulism.

Clinical Presentation:

Healthcare providers should be alert for symptoms consistent with botulism occurring after botulinum toxin injections. Initial botulism symptoms may include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, and difficulty breathing. These symptoms may be followed by a descending, symmetric muscle weakness that progresses over hours to days.

Common findings include:

- Muscle weakness, especially in areas beyond the injection site. Note especially symmetric or bilateral weakness in distinction to localized weakness at or near the injection site, which is expected.
- Dysphagia (difficulty swallowing)
- Dysarthria (speech difficulties)
- Ptosis (drooping eyelids)
- Respiratory difficulty
- Other cranial nerve palsies

Symptoms may develop hours to days post-injection.

Recommendations for Clinicians:

- **Maintain a high index of suspicion** for botulism in patients presenting with compatible symptoms following cosmetic Botox or other botulinum toxin injections.
- **Obtain a detailed history** of recent botulinum toxin exposure, including the name and location of the injecting provider and any available information about the brand, lot and dose.
- **Report suspected cases immediately** to the Massachusetts Department of Public Health by calling 617-983-6800 (24/7) or to the local board of health
- **Coordinate prompt clinical management**, including supportive care and consideration of botulinum antitoxin administration when indicated. Early treatment can improve outcomes.
- **Counsel patients** who report using or being interested in using botulinum toxin about potential adverse effects.
- **Advise patients to receive injections only from licensed providers** who are trained in proper administration of FDA-approved botulinum toxin products, preferably in a licensed or accredited healthcare setting.

MDPH is actively investigating these cases to identify the source and prevent further incidents.

Clinicians are urged to report any suspected cases promptly to facilitate timely public health response.

For additional information or questions, please contact the Massachusetts Department of Public Health, at 617-983-6800.